FDA Considering New Incentives For Safer Pain, Addiction Therapies

FDA wants to hear from stakeholders on whether new preapproval incentives are needed to encourage development of safer pain and addiction therapies at a public hearing slated for Sept. 17. The agency also wants advice on what additional factors to consider when it reviews new opioids, and whether the agency needs new authority from Congress. The agency announced the meeting Thursday (June 20) along with a new draft guidance that states FDA will start weighing broader public health effects as...